Considerations in Analyzing Single-Trough Concentrations Using Mixed-Effects Modeling

Journal of Clinical Pharmacology

Volumn 43, Issue 12, 2003, Pages 1307-1315

  Booth, Brian P ^a,b   Gobburu, Jogarao V S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Center for Drug Evaluation and Research   (United States)

Author keywords

Bayesian estimates; Bias; Population pharmacokinetics; Trough concentrations

Indexed keywords

ACCURACY; ARTICLE; BAYES THEOREM; BLOOD LEVEL; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DATA ANALYSIS; HUMAN; MODEL; MONTE CARLO METHOD; SAMPLING;

BAYES THEOREM; HUMANS; MODELS, THEORETICAL; PHARMACOKINETICS;

EID: 0242552670     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003258670     Document Type: Article

References (14)

1. U.S. Food and Drug Administration: Guidance for Industry: Population Pharmacokinetics. Rockville, MD: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 1999. Retrieved from www.fda.gov/cder/guidance/index.htm
2. Sheiner LB, Beal BL: Evaluation of methods for estimating population pharmacokinetic parameters III monoexponential model: routine clinical pharmacokinetic data. J Pharmacokin Biopharm 1983;11(3):303-319.
3. Gibaldi M, Perrier D: Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982.
4. Grasela TH, Antal EJ, Townsend RJ, Smith RB: An evaluation of population pharmacokinetics in therapeutic trials: Part I. Clin Pharmacol Ther 1986;39:605-612.
5. Jonsson EN, Wade JR, Karlsson MO: Comparison of some practical sampling strategies for population pharmacokinetic studies. J Pharmacokin Biopharm 1996;24(2):245-263.
6. Kowalski KG, Hutmacher MM: Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study. Stat Med 2001;20:75-91.
7. Beal SL: Things you may have wanted to ask about the ESTIMATION record but have been hesitant to ask. Population Analysis Group of Europe, Salamanca, Spain, 2000.
8. Lee IDP: Design and power of a population pharmacokinetic study. Pharm Res 2002;18:75-82.
9. Holford NHG: Bias and power of a population pharmacokinetic study. Clin Pharmacol Ther 2002;71:56.
10. Wade JR, Kelman AW, Howie CA, Whiting B: Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharm 1993; 21(2):209-222.
11. Aarons L, Balant LP, Mentre F, Morselli PL, Rowland M, Steimer J-L, et al: Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol 1996;49:251-254.
12. Gisleskog PO, Karlsson MO, Beal SL: Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn 2002;29(5-6):473-505.
13. Wählby U, Jonsson EN, Karlsson MO: Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokin Pharmacodyn 2001;28:231-252.
14. Gobburu JVS, Lawrence J: Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences. Pharm Res 2002;19:92-98.